Mereo BioPharma Q1 2026 net loss $6.7M; setrusumab regulatory dialogue initiated for pediatric OI

Mereo BioPharma Group plc

2026-Q1 EPS reported -$0.01

Net loss $6.7M vs $12.9M YoY; cash $36.2M as of March 31, expected runway into mid-2027.
Setrusumab Phase 3 studies missed primary fracture endpoint but achieved significant bone mineral density and PRO improvements; regulatory engagement for pediatric OI started.
Alvelestat partnership discussions ongoing; single Phase 3 trial (~220 patients) could start within 6 months of deal.
Vantictumab Phase 2 in osteopetrosis expected H2 2026 by partner āshibio; Mereo retains European rights.
R&D expenses $4.7M (+$0.8M YoY) driven by setrusumab manufacturing costs; G&A $4.0M (-$3.3M) due to ADR reimbursement and savings.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.75

Mereo BioPharma Group plc reported the first quarter ended March 31, 2026 results: net income Net loss for the first quarter of 2026 was $6.7 million.

Period: the first quarter ended March 31, 2026
Net income: Net loss for the first quarter of 2026 was $6.7 million
Result: reported results

Exact text from the filing

On May 12, 2026, Mereo BioPharma Group plc announced its financial results for the first quarter ended March 31, 2026 and provided an update on recent corporate developments.

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

Mereo BioPharma Group plc filing history →

Source: SEC EDGAR

accession 0001193125-26-218192

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.